Re: Hepalink IPO Document and what it says about RVX
in response to
by
posted on
Jan 28, 2020 06:41AM
"it appears from the HL doc that a Ph3 trial on the effect of ABL on CKD might be on the cards.."
Was this determined by the chart that summarizes the development status of their pipeline drugs, found on page 9 of the IPO Summary? (Type 2 diabetes with coronary heart disease)
Koo